LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

LLY

755.22

+3.01%↑

JNJ

153.86

-0.07%↓

UNH

378.43

-0.51%↓

ABBV

189.92

+3.08%↑

ABT

131.96

-0.98%↓

Search

Cellectar Biosciences Inc

Gesloten

0.24

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.23

Max

0.26

Belangrijke statistieken

By Trading Economics

Werknemers

11

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+300% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-2.7M

11M

Vorige openingsprijs

0.24

Vorige sluitingsprijs

0.24

Cellectar Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 dec 2024, 18:44 UTC

Belangrijke Marktbewegers

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Peer Vergelijking

Prijswijziging

Cellectar Biosciences Inc Prognose

Koersdoel

By TipRanks

300% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1 USD  300%

Hoogste 1 USD

Laagste 1 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Cellectar Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Financieel

$

Over Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.